US buyout giant KKR has been dealt a double blow after losing out in bidding wars for two British companies. The private equity firm confirmed on Monday it had been trumped in its pursuit of high-tech instruments maker Spectris as the company instead opted for a rival £4.4bn bid from Advent. This came after a KKR-led bid for Assura, the owner of hundreds of GP practices across the UK, was also rejected by the board in favour of a separate offer from listed fund PHP. It marks a rare setback for the New York-based buyout firm, whose staff were once dubbed “barbarians at the gates” for their aggressive culture. KKR’s wide-ranging takeover attempts in Britain also led to it being named as the preferred bidder for troubled utility giant Thames Water. However, it abandoned a £4bn rescue bid earlier this month amid a row over fines and executive bonuses. The private equity firm was founded in 1976 by Jerome Kohlberg, Henry Kravis and George Roberts with initial funding of $120,000 (£88,900) Its assets under management now total $638bn, according to figures from the end of last year. This includes a range of investments in the UK, including utility giant Northumbrian Water, PR firm FGS Global and festival operator Superstruct. KKR is one of a number of private equity deals circling British companies amid an exodus from the London Stock Exchange. But the buyout firm has been stymied in several of its recent efforts as competition for UK takeovers grows. Spectris, which makes instruments and software for use in industries such as pharmaceuticals, said it had agreed a £4.4bn takeover by Advent International, which it said was “fair and reasonable”. The FTSE 250 company had previously rejected two initial offers from KKR. KKR on Monday said that while it had not made a revised proposal, it was in the “advanced stages of due diligence and arranging financing commitments” and could still do so. KKR’s failed swoop for Assura comes after the NHS landlord recommended a £1.7bn bid tabled by the private equity firm alongside US infrastructure investor Stonepeak. But the approach sparked a backlash from major Assura investors amid concerns the company would be taken off the stock market at too low a price. Assura’s board had previously said that the KKR bid offered “materially less risk” than that of PHP. But it rowed back on Monday, saying PHP’s fresh bid “addressed some of the potential risks”. View Comments
Buyout giant KKR hit with double defeat in bid battles
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...